Oruka Therapeutics Inc

ORKA remains in a Stage 2 advancing regime following a Momentum Breakout, but price is currently extended above rising EMAs and tagged Extreme OB. Medium-term bullish structure supports continuation, but timing favors waiting for a pullback into the rising 9 and 20 EMA support zone before entering. Stalk for a better risk–reward entry into the momentum-driven uptrend.

• ↑BTIG reiterates Buy at $151 PT vs $86.79 current price
• ↑40.5% return past month driven by bullish moving-average crossover
• ↓Q2 loss of $94M with negative earnings yield underscores poor profitability